The organ procurement coordinator commonly must correct and maintain the arterial blood pressure during donor care. This article reviews considerations in the accurate measurement of the blood pressure, causes of hypertension and hypotension, and desirable standards to use in order to provide adequate organ perfusion. Recommendations are presented for treatment of hypotension in a titrated response of intravenous fluids, inotropic support, and vasopressor infusion to maintain the mean arterial pressure above 65 mm Hg. Collaborative interaction between the coordinator and physician consultant remains important throughout management of blood pressure changes during donor care.
Get full access to this article
View all access options for this article.
References
1.
ChemlaDHebertJLZamaniKCoiraultCLecarpentierY. A new formula for estimating mean aortic pressure. Lancet.1999; 353:1069–1070.
2.
LodatoRF. Arterial pressure monitoring. In: TobinMJ, ed. Principles and Practice of Intensive Care Monitoring.New York, NY: McGraw-Hill; 1998:733–749.
3.
FesslerHEShadeD. Measurement of vascular pressure. In: TobinMJ, ed. Principles and Practice of Intensive Care Monitoring.New York, NY: McGraw-Hill; 1998:91–106.
4.
SeneffM. Central venous catheters. In: RippeJMIrwinRSFinkMPCerraFB, ed. Intensive Care Medicine.3rd ed.Boston, Mass: Little, Brown; 1996:15–36.
5.
KwokMHJoyntGMTanP. A comparison of central venous pressure and common iliac venous pressure in critically ill mechanically ventilated patients. Crit Care Med.1998;* 26:461–464.
6.
PresHLSuffrediniAF. Pulmonary artery catheterization: Insertion and quality control. In: TobinMJ, ed. Principles and Practice of Intensive Care Monitoring.New York, NY: McGraw-Hill; 1998:773–795.
7.
RowleyKMClubbKSSmithGJCabinHS. Right-sided infective endocarditis as a consequence of flow-directed pulmonary artery catheterization. N Engl J Med.1984;* 311:1152–1156.
8.
CittanovaMLLeblancILegendreCMouquetCRiouBCoriatP. Effects of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney transplant recipients. Lancet.1996;348:1620–1622.
9.
NovitzkyDWicombWNCooperDKCRoseAGFraserRCBarnardCN. Electrocardiographic, hemodynamic and endocrine changes occurring during experimental brain death in the Chacma baboon. J Heart Transplant.1984;4:63–69.
10.
BittnerHBChenEPKendallSWHTrigtPV. Brain death alters cardiopulmonary hemodynamics and impairs right ventricular power reserve against an elevation of pulmonary vascular resistance. Chest.1997;111:706–711.
11.
NovitzkyD. Donor management: State of the art. Transplant Proc.1997;29:3773–3775.
12.
Darracott-CankovicSStovenPGIWheeldonDWallworkJWellsFEnglishTAH. Effect of donor heart damage on survival after transplantation. Eur J Cardiothorac Surg.1989;3:525–532.
13.
ShivalkerBVan LoonJWielandW. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation.1993;87:230–239.
14.
PownerDJHendrickANyhuisAStrateR. Changes in serum catecholamines in brain dead patients. J Heart Lung Transplant.1992;111:1046–1053.
WhiteMWiechmannRJRodenRL. Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Circulation.1995;92:2183–2189.
17.
OwenVJBurtonPBJMichelMC. Myocardial dysfunction in donor hearts. Circulation.1999;99:2565–2570.
18.
PownerDJHendrickALaglerRNgRHMaddenRL. Hormonal changes in brain dead patients. Crit Care Med.1990; 18:702–708.
19.
DebelakLPollackRReckardC. Arginine vasopressin versus desmopressin for the treatment of diabetes insipidus in the brain dead organ donor. Transplant Proc.1990;22:351–352.
20.
PennefatherSHBullockREDarkJH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation.1993;56:1418–1422.
21.
PinskyMR. Hemodynamic profile interpretation. In: TobinMJ, ed. Principles and Practice of Intensive Care Monitoring.New York, NY: McGraw-Hill; 1998:871–888.
22.
MuggeADanielWG. Transesophageal echocardiography. In: TobinMJ, ed. Principles and Practice of Intensive Care Monitoring.New York, NY: McGraw-Hill; 1998:931–962.
23.
RirieDGButterworthJFRoysterRLMacGregorDAZalogaGP. Triiodothyronine increases contractility independent of beta-adrenergic receptors or stimulation of cyclic 3–5-adenosine monophosphate. Anesthesiology.1995;82:1004–1012.
24.
TimekTBonzADillmanRVahlCFHaglS. The effect of triiodothyronine on myocardial contractile performance after ephinephrine exposure: Implications for donor heart management. J Heart Lung Transplant.1998;17: 931–940.
25.
NovitzkyD. Selection and management of cardiac allograft donors. Curr Opin Cardiol.1996;11:174–182.
26.
GoarinJPCohenSRiouB. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg.1996;83:41–47.
27.
HaglC.SzaboGSebeningC. Is the brain death related endocrine dysfunction an indication for hormonal substitution therapy in the early period?Eur J Med Res.1997;2:437–440.
28.
IwaiASakanoTUenishiMSugimotoHYoshiokaTSugimotoT. Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain dead patients. Transplantation.1989;48:613–617.
29.
PennefatherSHBullockREMantleDDarkJH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation.1995;59:58–62.
